Cyprium Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$7M
Cyprium Therapeutics General Information
Description
Operator of a biotech company intended for the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company's platform comes up with a subcutaneous injectable formulation of copper histidine for offering an early treatment to patients with the disease, enabling physicians to improve the neurodevelopmental outcomes and survival.
Contact Information
Website
www.cypriumtx.comCorporate Office
- 1111 Kane Concourse
- Suite 301
- Bay Harbor Islands, FL 33154
- United States
Corporate Office
- 1111 Kane Concourse
- Suite 301
- Bay Harbor Islands, FL 33154
- United States
Cyprium Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 05-Oct-2021 | $7M | Completed | Clinical Trials - Phase 3 |
Cyprium Therapeutics FAQs
-
When was Cyprium Therapeutics founded?
Cyprium Therapeutics was founded in 2017.
-
Where is Cyprium Therapeutics headquartered?
Cyprium Therapeutics is headquartered in Bay Harbor Islands, FL.
-
What industry is Cyprium Therapeutics in?
Cyprium Therapeutics’s primary industry is Drug Discovery.
-
Is Cyprium Therapeutics a private or public company?
Cyprium Therapeutics is a Private company.
-
What is Cyprium Therapeutics’s current revenue?
The current revenue for Cyprium Therapeutics is .
-
How much funding has Cyprium Therapeutics raised over time?
Cyprium Therapeutics has raised $7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process